Abstracts Archive - Page 579 of 2425 - ACR Meeting Abstracts

Abstract Number: 0404 • ACR Convergence 2021
Perifollicular Hypopigmentation in Systemic Sclerosis: Associations with Clinical Features and Internal Organ Involvement
Melody Chung¹, Jamie Perin¹, Carrie Richardson², Christopher Mecoli³, Fred Wigley¹ and Zsuzsanna McMahan⁴, ¹Johns Hopkins University, Baltimore, MD, ²Rush University Medical Center, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Among the autoimmune rheumatic diseases, there is precedent for utilizing cutaneous manifestations of systemic disease as clues to clinical phenotype and disease prognosis. Though…
Abstract Number: 0403 • ACR Convergence 2021
Effect of Nintedanib on KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
Shervin Assassi¹, Christopher Denton², Maurizio Cutolo³, Tracy Luckhardt⁴, Claudia Diefenbach⁵, Carina Ittrich⁶, Margarida Alves⁷ and Masataka Kuwana⁸, ¹University of Texas McGovern Medical School at Houston, Houston, TX, ²University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ³Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ⁴University of Alabama, Birmingham, AL, ⁵Boehringer Ingelheim Pharma GmBH, Biberach an der Riss, Germany, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁸Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Krebs von den Lungen-6 (KL-6), a marker of lung epithelial and endothelial injury, has been associated with progression of interstitial lung disease associated with…
Abstract Number: 0402 • ACR Convergence 2021
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
Alain Lescoat¹, Susan Murphy², Yen Chen³, Nadia Vann¹, David Cella⁴ and Dinesh Khanna³, ¹Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Michigan, Grosse Ile, MI, ³University of Michigan, Ann Arbor, MI, ⁴Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…
Abstract Number: 0397 • ACR Convergence 2021
Safety and Persistence of Monthly Intravenous Iloprost in Systemic Sclerosis
Patrícia Martins¹, Eduardo Dourado¹, João Eurico Fonseca¹, Vasco C Romão¹ and Catarina Resende², ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ²Centro Hospitalar Universitário Lisboa Norte, Rheumatology Department, Lisbon, Portugal
Background/Purpose: Vasculopathy is a crucial feature of systemic sclerosis (SSc). Raynaud’s phenomenon (RP) and digital ulcers (DU) greatly impact the patients’ quality of life. Intravenous…
Abstract Number: 0408 • ACR Convergence 2021
A Histogram-based Densitometry Index to Support the Identification and the Assessment of Severity of Interstitial Lung Disease in Systemic Sclerosis: Applicability in Conventional and Low-dose Computed Tomography
COSIMO BRUNI¹, Alexandru Garaiman², Lorenzo Tofani³, Suzana Jordan⁴, Carmen-Marina Mihai⁴, Rucsandra Dobrota⁴, Muriel ELHAI⁵, Mike Oliver Becker⁴, Marco Matucci-Cerinic³ and Oliver Distler⁶, ¹University of Florence, Department of Rheumatology, Florence, Italy & Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Florence, Italy, ²University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³University of Florence, Florence, Italy, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁶Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland
Background/Purpose: High resolution computed tomography (conventional CT) represents the diagnostic gold standard for systemic sclerosis-related interstitial lung disease (SSc-ILD). A low-dose 9-slices (reduced) CT protocol…
Abstract Number: 0407 • ACR Convergence 2021
The Clinical Role of T1 Mapping Cardiac Magnetic Resonance Imaging for Detecting Cardiac Involvement in the Early Stage of Systemic Sclerosis
Munkhtuul Purevsuren¹, Masae Uehara¹, Masato Ishizuka¹, Toru Hara¹, Nobutaka Kakuda¹, Taeko Tsuji¹, Tadashi Yamazaki¹, Miyazaki Miki², Hayakazu Sumida², Ayumi Yoshizaki², Yoshihide Asano², Shinichi Sato³, Masaru Hatano¹ and Komuro Issei¹, ¹1. Department of Cardiovascular Medicine, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan., Tokyo, Japan, ²2. Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan., Tokyo, Japan, ³Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin and internal organs tissue fibrosis including the myocardium. Cardiovascular magnetic resonance (CMR) parametric mapping is a promising…
Abstract Number: 0405 • ACR Convergence 2021
Retrospective Study on the Prognostic Value of Cardiac Magnetic Resonance Imaging Abnormalities in Systemic Sclerosis
Hao Cheng Shen¹, Catherine Faucher², Anne Chin³, Carl Chartrand-Lefebvre³, Ragui Chehata⁴, Julia Cadrin-Tourigny⁵, Francois-Pierre Mongeon⁶, Jean-Paul Makhzoum⁷, Océane Landon-Cardinal⁸, Josiane Bourré-Tessier⁸, Éric Rich⁹, Jean-Richard Goulet⁸, Paul R Fortin¹⁰, Jean-Luc Senécal⁸ and Sabrina Hoa⁸, ¹Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Department of Medicine, Université Laval, Québec, QC, Canada, ³Department of Radiology, Centre hospitalier de l’Université de Montréal, Montréal, QC, Canada, ⁴Department of Medicine, Université de Montréal, Montreal, Montréal, QC, Canada, ⁵Division of Non-Invasive Cardiology, Department of Specialized Medicine, Montreal Heart Institute; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁶Division of electrophysiology, Department of Specialized Medicine, Montreal Heart Institute; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁷Division of Internal Medicine, Hôpital Sacré-Coeur de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁸Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁹Division of Rheumatology, Centre hospitalier de l’Université de Québec-Université Laval, Montréal, QC, Canada, ¹⁰CHU de Quebec - Universite Laval, Québec City, QC, Canada
Background/Purpose: Cardiac involvement is a leading cause of death in systemic sclerosis (SSc). Cardiac MRI (CMR) is useful in the early assessment of cardiac disease.…
Abstract Number: 0409 • ACR Convergence 2021
Factors Predicting Mortality in an Indian Cohort of Systemic Sclerosis
T G Sundaram¹, Durga P Misra¹, Rudrarpan Chatterjee¹, Sakir Ahmed² and Vikas Agarwal³, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Kalinga Institute of Medical Sciences, Bhubaneswar, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Systemic sclerosis is characterised by high morbidity and mortality due to disease-related or treatment-related complications.Methods: Data of patients of systemic sclerosis between 1990 and…
Abstract Number: 0411 • ACR Convergence 2021
Pharmacokinetics, Safety, and Efficacy of Subcutaneous Brodalumab for Systemic Sclerosis with Moderate-to-severe Skin Thickening: A Single-arm, Open-label, Multi-dose, Phase 1 Trial
Takemichi Fukasawa¹, Ayumi Yoshizaki², Satoshi Ebata² and Shinichi Sato², ¹Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: The exact role of interleukin-17 in systemic sclerosis (SSc) has not been established. This trial assessed the pharmacokinetics (PK), safety, and efficacy of multiple…
Abstract Number: 0410 • ACR Convergence 2021
Long-term Outcomes of Vascular Grafting of Medium Sized Vessels of the Wrist and Hand in Patients with Medication Refractory Systemic Sclerosis Related Raynaud’s Phenomenon at the University of Pennsylvania from 2009-2019
Nora Sandorfi¹, Chris Derk² and Nora Hajnoczky³, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Albert Einstein Healthcare Network, Wallingford, PA
Background/Purpose: Raynaud’s phenomenon (RP) seen in patients with an underlying autoimmune rheumatic disorder have both functional and structural dysfunction at the microvascular level and in…
Abstract Number: 0406 • ACR Convergence 2021
Gender Differences in Clinical Features and Outcomes of Systemic Sclerosis: Analysis of Reuma.pt/SSc Registry
Raquel Freitas¹, Patrícia Martins², Eduardo Dourado², Tânia Santiago³, Francisca Guimarães⁴, Bruno Fernandes⁵, Salomé Garcia⁶, Beatriz Samões⁷, Ana Pinto⁸, Nuno Gonçalves⁹, Maria Lourenço¹⁰, Emanuel Costa¹¹, Margarida Rocha¹², Maura Couto¹³, Ana Catarina Duarte¹, Filipe Araújo¹⁴, Inês Cordeiro², Fátima Godinho¹, Catarina Resende¹⁵, Maria Joo Salvador¹⁶, Ana Cristina Cordeiro¹ and Maria José Santos¹⁷, ¹Hospital Garcia de Orta, Rheumatology department, Almada, Portugal, ²Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ³Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁴Unidade Local de Saúde do Alto Minho, Rheumatology department, Ponte de Lima, Portugal, ⁵Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Braga, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁷Rheumatology Department, Centro Hospitalar Vila Nova de Gaia, VIla Nova de Gaia, Portugal, ⁸Local Health Unit of Guarda, Portugal, Barcelos, Portugal, ⁹Centro Hospitalar Lisboa Ocidental, Rheumatology Department; Hospital Central do Funchal, Lisboa, Portugal, ¹⁰Hospital Egas Moniz, Barcelos, Portugal, ¹¹Hospital de Braga, Braga, Portugal, ¹²Centro Hospitalar Universitário Lisboa Norte, Rheumatology Department, Faro, Portugal, ¹³Centro Hospitalar Tondela - Viseu, Rheumatology Department, Linda a Velha, Portugal, ¹⁴Hospital de Sant'Ana, Rheumatology and Osteoporosis department, Parede, Portugal, ¹⁵Centro Hospitalar Universitário Lisboa Norte, Rheumatology Department, Lisbon, Portugal, ¹⁶Centro Hospitalar e Universitário de Coimbra, Rheumatology Department, Coimbra, Portugal, ¹⁷Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal
Background/Purpose: Systemic sclerosis (SSc) is a rare connective tissue disease of unknown etiology, with a broad spectrum of clinical and laboratory features. Evidence for the…
Abstract Number: 0400 • ACR Convergence 2021
Item Development for the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP) Questionnaire
John Pauling¹, Lesley Ann Saketkoo², Dinesh Khanna³, Christopher Denton⁴, Tracy Frech⁵, Ariane Herrick⁶, Laura Hummers⁷, Ami Shah⁸ and Robyn Domsic⁹, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ³University of Michigan, Ann Arbor, MI, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁵University of Utah, Salt Lake City, UT, ⁶University of Manchester, Salford, United Kingdom, ⁷Johns Hopkins Univerisity, Baltimore, MD, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The episodic and uniquely personalised nature of Raynaud’s phenomenon (RP) has led to reliance upon self-report to capture how patients ‘feel’ and ‘function’. Existing…
Abstract Number: 0381 • ACR Convergence 2021
How Do Clinical and Socioeconomic Factors Impact on Work Disability in Early Axial Spondyloarthritis? Five-year Data from the DESIR Cohort
Elena Nikiphorou¹, Annelies Boonen², Bruno Fautrel³, Pascal Richette⁴, Robert Landewé⁵, Désirée van der Heijde⁶ and Sofia Ramiro¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands, ³Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ⁴Lariboisiere Hospital, Paris, France, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: There remains substantial unmet need to study work disability (WD) in early axSpA. Previous studies suggest that treatment interventions alone do not improve work…
Abstract Number: 0352 • ACR Convergence 2021
Native American and African American Rheumatic Disease Patients Exhibit Accelerated Biological Aging Compared to European Americans
Joseph Kheir, Carla Guthridge, Nicolas Dominguez, Wade DeJager, Sarah Cooper, Joel Guthridge and Judith James, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The universal process of aging is associated with increased risk of disease and death as a result of changing physiologic and molecular processes. In…
Abstract Number: 0289 • ACR Convergence 2021
Developing a Score to Predict Preclinical Interstitial Lung Disease in Patients with Rheumatoid Arthritis – a Cross-Sectional Study from the ESPOIR Cohort
Pierre Antoine Juge¹, Benjamin Granger², Marie-Pierre Debray³, Esther Ebstein⁴, Fabienne Louis-sidney⁵, Joanna Kedra⁶, Raphaël Borie⁷, Arnaud Constantin⁸, Bernard Combe⁹, Rene-Marc FLIPO¹⁰, Xavier Mariette¹¹, Olivier Vittecoq¹², Alain Saraux¹³, Guillermo CARVAJAL-ALEGRIA¹⁴, Jean Sibilia¹⁵, Francis Berenbaum¹⁶, Caroline Kannengiesser¹⁷, Catherine Boileau¹⁷, Bruno Crestani¹⁸, Bruno Fautrel¹⁹ and Philippe Dieudé²⁰, ¹Hopital Bichat-Claude Bernard, Service de Rhumatologie, Paris, France, ²Département de Santé Publique, Hopital de la Pitié Salpétrière, Paris, France, ³Hopital Bichat, Service de Radiologie, Paris, France, ⁴Hopital Bichat, Service de Rhumatologie, Paris, ⁵University Hospital Martinique, Fort de France, Martinique, ⁶Sorbonne Universit, Institut Pierre Louis d'Epidmiologie et de Sant Publique, Paris, France, ⁷Hopital Bichat, Service de Pneumologie, Paris, ⁸Toulouse University Hospital, Toulouse Cedex 9, France, ⁹CHU Montpellier Montpellier University, Montpellier, France, ¹⁰Lille University Hospital, Lille, France, ¹¹Université Paris- Saclay, Rheumatology, Paris, France, ¹²CHU de Rouen, Service de Rhumatologie, Rouen, France, ¹³CHU de Brest, Brest Cedex, France, ¹⁴CHU de Brest, Service de Rhumatologie, Brest, ¹⁵CHU de Strasbourg, Service de Rhumatologie, Strasbourg, France, ¹⁶Sorbonne Universit - hopital Saint-Antoine, Paris, France, ¹⁷CHU de Bichat, Service de Génétique, Paris, France, ¹⁸Hopital Bichat, Paris University, Paris, France, ¹⁹Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ²⁰CHU de Bichat, Service de Rhumatologie, Paris, France
Background/Purpose: Interstitial lung disease (ILD) can be detected in 20% to 60% of patients with rheumatoid arthritis (RA) on high-resolution computed-tomography (HRCT) chest scan and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].